A Phase 2 Study of ATH434 a Novel Inhibitor of α-Synuclein Aggregation for the Treatment of Multiple System Atrophy
Objective: Describe baseline fluid and neuroimaging biomarker data of an early MSA study population Background: MSA is a rapidly progressive neurodegenerative disorder characterized by aggregated…Syllable-based speech characteristics as potential biomarker for differential diagnosis of Parkinson’s disease, multiple system atrophy, and cerebellar ataxia
Objective: To analyze syllable-based speech characteristics in patients with Parkinson’s disease (PD), multiple system atrophy (MSA), and cerebellar ataxia (CA) to determine if there is…Safety and Efficacy of the Anti-alpha Synuclein Monoclonal Antibody Lu AF82422 for the Treatment of Patients with MSA: Results from the Phase 2 AMULET Trial
Objective: Assess the efficacy and safety of monthly IV infusions with the anti-alpha synuclein [a-syn] monoclonal antibody Lu AF82422 for the treatment of patients with…Lyme disease presenting as a rapidly progressive MSA-C look alike
Objective: We report two cases of encephalomyelitis due to Lyme disease with cerebellar ataxia and autonomic symptoms, which presented with a rapidly progressive MSA-like phenotype.…The Clinical Implication of Dysphagia in Patients with Multiple System Atrophy
Objective: This study aimed to explore the correlation between dysphagia and key clinical features in Multiple System Atrophy (MSA) patients, along with investigating the link…Effect of rehabilitation therapy on the motor functions in patients with multiple system atrophy
Objective: We aim to evaluated the effect of rehabilitation therapy on the motor symptoms and activities of daily living in patients with MSA using an…Altered activity of lysosomal hydrolases in monocyte-derived macrophages as potential biomarker for differential diagnosis of multiple system atrophy
Objective: The aim was to assess the possibility of differentiating synucleinopathies (Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA) by lysosomal…Role of the Alpha-synuclein Seed Amplification Assay in Parkinson’s Disease Clinical Trials: A Case Report of Multiple System Atrophy Misdiagnosed as Parkinson’s Disease
Objective: Report a patient with Multiple System Atrophy (MSA) misdiagnosed as Parkinson’s disease (PD) and enrolled in a clinical trial for PD treatment with Mesenchymal…Multifaceted Challenges in Multisystem Atrophy Management: Medication Sensitivity, Emotional Lability, and Increased Fall Risk
Objective: Multisystem atrophy (MSA) epitomizes a formidable quandary within neurological and geriatric disciplines, delineated by complex manifestations encompassing autonomic dysfunction, parkinsonism, and cerebellar ataxia. This…Combining alpha-synuclein PET and seeded amplification assays to improve the diagnostic accuracy of Multiple System Atrophy of the Parkinsonian subtype (MSA-P)
Objective: To determine whether the combination of spatial (PET [18F]ACI-12589) and conformational (skin seed amplification assay; SAA) a-syn data aids the early differential diagnosis of…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 1554
- Next Page »